Back in July when I started this blog I posted on the economics of injectable pharmaceuticals.
Momenta Pharma had released news they would be producing a copycat version of a popular blood thinner manufactured by Sanofi-Aventis. The share price of Momenta shot up by 70% on the news while the share prices of SA and other related companies barely nudged.
At the time I provided insights on why this was a blip and how you could make a little money. The advice was not for the faint-of-heart.
Is Momenta a good buy? Perhaps it is based on its R&D activities but not quite yet on the news of a generic Lovenox.
Btw had you taken my advice on July 31, 2010 you could have reeled in an 86% ROI by mid-September.
Keep an eye on Momenta for more news in the future.
Cheers!
No comments:
Post a Comment